What have we learned from past failures of investigational drugs for Alzheimer’s disease?

References

• Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397:1577–1590.
   PubMed Web of Science ®Google Scholar
• Prokopenko D, Morgan SL, Mullin K, et al. Whole-genome sequencing reveals new Alzheimer’s disease-associated rare variants in loci related to synaptic function and neuronal development. Alzheimers Dement. 2021;17:1509–1527.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20:68–80.
   PubMed Web of Science ®Google Scholar
• Chen CD, Joseph-Mathurin N, Sinha N, et al. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer's disease. Acta Neuropathol. 2021;142:689–706.
   PubMed Web of Science ®Google Scholar
• Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol. 2020;140:417–447.
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456.
   PubMed Web of Science ®Google Scholar
• Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157–172.
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.
   PubMed Web of Science ®Google Scholar
• Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505–508.
   PubMed Web of Science ®Google Scholar
• Koss DJ, Jones G, Cranston A, et al. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline. Acta Neuropathol. 2016;132:875–895.
   PubMed Web of Science ®Google Scholar
• Gaikwad S, Puangmalai N, Bittar A, et al. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia. Cell Rep. 2021;36:109419.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73–88.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ippati S, Watling M, et al. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2021 Sep 17.
   PubMed Web of Science ®Google Scholar
• Howard R, Zubko O, Bradley R, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2020;77:164–174.
   PubMed Web of Science ®Google Scholar
• Jackson M. Cortexyme Alzheimer’s study fails; drug slows cognitive decline in some patients. Scrip. 2021 Oct 26.
   Google Scholar
• Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77:735–745.
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Abdalla N. Design and sample size considerations for Alzheimer’s disease prevention trials using multistate models. Clin Trials. 2019;16:111–119.
   PubMed Web of Science ®Google Scholar
• McDade E, Llibre-Guerra JJ, Holtzman DM, et al. The informed road map to prevention of Alzheimer Disease: a call to arms. Mol Neurodegener. 2021;16:49.
   PubMed Web of Science ®Google Scholar
• Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat Med. 2021;27:1187–1196.
   PubMed Web of Science ®Google Scholar
• Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b/3 clinical trial. JAMA Neurol. 2021;78:293–301.
   PubMed Web of Science ®Google Scholar
• Lopez Lopez C, Tariot PN, Caputo A, et al. The Alzheimer’s prevention initiative generation program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease. Alzheimers Dement (N Y). 2019;5:216–227.
   PubMedGoogle Scholar
• Rios-Romenets S, Lopera F, Sink KM, et al. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer’s prevention initiative (API) autosomal-dominant Alzheimer’s disease Colombia trial. Alzheimers Dement. 2020;16:1023–1030.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2019;28:967–975.
   PubMed Web of Science ®Google Scholar
• Liu KY, Howard R. Can we learn lessons from the FDA’s approval of aducanumab? Nat Rev Neurol. 2021;17:715–722.
   PubMed Web of Science ®Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–1704.
   PubMed Web of Science ®Google Scholar
• Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.
   PubMedGoogle Scholar
• Rosenberg PB, Lanctôt KL, Herrmann N, et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer’s disease. J Alzheimers Dis. 2016;54:373–381.
   PubMed Web of Science ®Google Scholar
• Egan MF, Mukai Y, Voss T, et al. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther. 2019;11:68.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Bellomo A, et al. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients? Ageing Res Rev. 2019b;55:100948.
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–350.
   PubMed Web of Science ®Google Scholar
• Sur C, Kost J, Scott D, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain. Brain. 2020;143:3816–3826.
   PubMed Web of Science ®Google Scholar
• Hampel H, Vassar R, De Strooper B, et al. The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry. 2021;89:745–756.
   PubMed Web of Science ®Google Scholar
• Sturchio A, Dwivedi AK, Young CB, et al. High cerebrospinal amyloid-β42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine. 2021;38:100988.
   PubMedGoogle Scholar
• Grogan K. AC immune and roche candidate latest in a long line of misses. Scrip. 2020 Sept 24.
   Google Scholar
• Shugart J. Biogen shelves gosuranemab after negative alzheimer’s trial. Alzheimer Res Forum. 2021 Jun 18.
   Google Scholar
• Jackson M. Cautious optimism as Genentech/AC immune’s anti-tau antibody slows cognitive decline. Scrip. 2021 Aug 31.
   Google Scholar
• Bowman Rogers M. To block Tau’s proteopathic spread, antibody must attack its mid-region. Alzheimer Research Forum. 2018 Apr 5.
   Google Scholar
• Satlin A, Wang J, Logovinsky V, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimers Dement. 2016;2:1–12.
   Google Scholar
• Qian J, Betensky RA, Hyman BT, et al. Association of APOE genotype with heterogeneity of cognitive decline rate in Alzheimer disease. Neurology. 2021;96:e2414–e2428.
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13:80.
   PubMed Web of Science ®Google Scholar
• Karlawish J, Grill JD. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat Rev Neurol. 2021;17:523–524.
   PubMed Web of Science ®Google Scholar
• Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 2014;82:1536–1542.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–56.
   PubMed Web of Science ®Google Scholar
• Peric A, Annaert W. Early etiology of Alzheimer’s disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol. 2015;129:363–381.
   PubMed Web of Science ®Google Scholar
• Taubes A, Nova P, Zalocusky KA, et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease. Nat Aging. 2021;1:932–947.
   Google Scholar
• Cross DJ, Huber BR, Silverman MA, et al. Intranasal paclitaxel alters alzheimer’s disease phenotypic features in 3xTg-AD mice. J Alzheimers Dis. 2021;83:379–394.
   PubMed Web of Science ®Google Scholar
• Dionisio-Santos DA, Karaahmet, B, Belcher, EK, et al. Evaluating effects of glatiramer acetate treatment on amyloid deposition and tau phosphorylation in the 3xTg mouse model of alzheimer’s disease. Front Neurosci. 2021;15:758677.
   PubMed Web of Science ®Google Scholar
• Hershey LA, Tarawneh R. Clinical efficacy, drug safety, and surrogate endpoints: has aducanumab met all of its expectations? Neurology. 2021;97:517–518.
   PubMed Web of Science ®Google Scholar
• Planche V, Villain N. US food and drug administration approval of aducanumab-is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol. 2021;78:1307–1308.
   PubMed Web of Science ®Google Scholar
• Alexander GC, Knopman DS, Emerson SS, et al. Revisiting FDA approval of aducanumab. N Engl J Med. 2021;385:769–771.
   PubMed Web of Science ®Google Scholar
• Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) phase 1b study in alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8:414–424.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med. 2019;380:2307–2316.
   PubMed Web of Science ®Google Scholar
• Kwon D. Failure of genetic therapies for Huntington’s devastates community. Nature. 2021;593:180.
   PubMedGoogle Scholar
• Yeung CHC, Lau KWD, Au Yeung SL, et al. Amyloid, tau and risk of Alzheimer’s disease: a Mendelian randomization study. Eur J Epidemiol. 2021;36:81–88.
   PubMed Web of Science ®Google Scholar
• In T’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345:1515–1521.
   PubMed Web of Science ®Google Scholar
• Josefson D. Statins may reduce risk of Alzheimer’s disease. BMJ. 2000;321:1040.
   PubMedGoogle Scholar
• Rönnemaa E, Zethelius B, Sundelöf J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology. 2008;71:1065–1071.
   PubMed Web of Science ®Google Scholar
• Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019;92:e2070–e2080.
   PubMed Web of Science ®Google Scholar
• Mejías-Trueba M, Pérez-Moreno MA, Fernández-Arche MÁ. Systematic review of the efficacy of statins for the treatment of Alzheimer’s disease. Clin Med (Lond). 2018;18:54–61.
   PubMed Web of Science ®Google Scholar
• Craft S, Raman R, Chow TW, et al. Safety, efficacy, and Feasibility of Intranasal Insulin for the treatment of mild cognitive impairment and Alzheimer's disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77:1099–1109.
   PubMed Web of Science ®Google Scholar
• Bowman Rogers M. Lecanemab sweeps up toxic Aβ protofibrils, catches eyes of trialists. Alzheimer Res Forum. 2021 Nov 26.
   Google Scholar
• Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer’s disease. Trends Pharmacol Sci. 2020;41:434–445.
   PubMed Web of Science ®Google Scholar
• Park HJ, Friston K. Structural and functional brain networks: from connections to cognition. Science. 2013;342:1238411.
   PubMed Web of Science ®Google Scholar
• Bressler SL, Menon V. Large-scale brain networks in cognition: emerging methods and principles. Trends Cogn Sci. 2010;14:277–290.
   PubMed Web of Science ®Google Scholar
• Berron D, van Westen D, Ossenkoppele R, et al. Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease. Brain. 2020;143:1233–1248.
   PubMed Web of Science ®Google Scholar
• Gonneaud J, Baria AT, Binette AP, et al. Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease. Nat Commun. 2021;12:5346.
   PubMed Web of Science ®Google Scholar
• Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186–198.
   PubMed Web of Science ®Google Scholar